DSGN vs. ATAI, SGMO, SYRS, DTIL, BNR, GYRE, IRWD, LQDA, OCUL, and IMNM
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Atai Life Sciences (ATAI), Sangamo Therapeutics (SGMO), Syros Pharmaceuticals (SYRS), Precision BioSciences (DTIL), Burning Rock Biotech (BNR), Gyre Therapeutics (GYRE), Ironwood Pharmaceuticals (IRWD), Liquidia (LQDA), Ocular Therapeutix (OCUL), and Immunome (IMNM).
Atai Life Sciences (NASDAQ:ATAI) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
Atai Life Sciences has higher revenue and earnings than Design Therapeutics. Atai Life Sciences is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.
Atai Life Sciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.
28.4% of Atai Life Sciences shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 31.2% of Atai Life Sciences shares are owned by company insiders. Comparatively, 31.2% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Atai Life Sciences had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Atai Life Sciences and 1 mentions for Design Therapeutics. Atai Life Sciences' average media sentiment score of 0.94 beat Design Therapeutics' score of 0.43 indicating that Design Therapeutics is being referred to more favorably in the news media.
Atai Life Sciences presently has a consensus price target of $10.50, suggesting a potential upside of 568.79%. Design Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 62.96%. Given Design Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Atai Life Sciences is more favorable than Design Therapeutics.
Design Therapeutics has a net margin of 0.00% compared to Design Therapeutics' net margin of -12,810.51%. Atai Life Sciences' return on equity of -20.79% beat Design Therapeutics' return on equity.
Atai Life Sciences received 316 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 65.99% of users gave Atai Life Sciences an outperform vote while only 34.48% of users gave Design Therapeutics an outperform vote.
Summary
Atai Life Sciences beats Design Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
